Teplizumab - preventative approaches to type 1 diabetes mellitus

被引：0
作者：
Seewoodhary, Jason [1 ]
Silveira, Angela [2 ]
机构：
[1] NHS Northwest London, Brent Integrated Hlth Board, London, England
[2] Saskatchewan Hlth Author, Publ Hlth & Prevent Med, Saskatoon, SK, Canada
来源：
PRACTICAL DIABETES | 2023年 / 40卷 / 02期
关键词：
teplizumab; type 1 diabetes mellitus; immunotherapy; anti-CD3; screening; INSULIN; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapies offer the potential to reprogramme the immune system to halt autoimmune destruction of insulin-producing beta-cells within the pancreas, dealing with the root cause of type 1 diabetes (T1DM) for the first time. Leading on from this, teplizumab, the first drug in this class, has been found to delay the onset of T1DM by an average of three years in people stratified high risk for developing T1DM. This review will critically consider the evidence basis underlying the utility of teplizumab in the management of T1DM. Copyright (c) 2023 John Wiley & Sons.
引用
收藏
页码：35 / +
页数：5
相关论文
共 50 条
  • [21] Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
    Hagopian, William
    Ferry, Robert J., Jr.
    Sherry, Nicole
    Carlin, David
    Bonvini, Ezio
    Johnson, Syd
    Stein, Kathryn E.
    Koenig, Scott
    Daifotis, Anastasia G.
    Herold, Kevan C.
    Ludvigsson, Johnny
    DIABETES, 2013, 62 (11) : 3901 - 3908
  • [22] Recent advances in the treatment of type 1 diabetes mellitus
    Schloot, N. C.
    Roden, M.
    Bornstein, S. R.
    Brendel, M. D.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (05) : 172 - 175
  • [23] Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
    Ana Luisa Perdigoto
    Paula Preston-Hurlburt
    Pamela Clark
    S. Alice Long
    Peter S. Linsley
    Kristina M. Harris
    Steven E. Gitelman
    Carla J. Greenbaum
    Peter A. Gottlieb
    William Hagopian
    Alyssa Woodwyk
    James Dziura
    Kevan C. Herold
    Diabetologia, 2019, 62 : 655 - 664
  • [24] New Approaches to the Immunotherapy of Type 1 Diabetes Mellitus Using Interleukin-27
    Zamani, Fatemeh
    Almasi, Shohreh
    Kazemi, Tohid
    Esfahlan, Rana Jahanban
    Aliparasti, Mohammad Reza
    ADVANCED PHARMACEUTICAL BULLETIN, 2015, 5 : 599 - 603
  • [25] Immunotherapies in Diabetes Mellitus Type 1
    Gupta, Smita
    MEDICAL CLINICS OF NORTH AMERICA, 2012, 96 (03) : 621 - +
  • [26] On type 1 diabetes mellitus pathogenesis
    Paschou, Stavroula A.
    Papadopoulou-Marketou, Nektaria
    Chrousos, George P.
    Kanaka-Gantenbein, Christina
    ENDOCRINE CONNECTIONS, 2018, 7 (01): : R38 - R46
  • [27] Comparative evaluation of pathophysiology of type 1 diabetes and gestational diabetes mellitus: A review
    Sharma, Amisha
    Priyanka
    Sharma, Amarish Kumar
    ANNALS OF PHYTOMEDICINE-AN INTERNATIONAL JOURNAL, 2021, 10 (01): : 123 - 131
  • [28] Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus
    Galligan, A.
    Greenaway, T. M.
    INTERNAL MEDICINE JOURNAL, 2016, 46 (05) : 540 - 549
  • [29] Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function
    Fanaropoulou, Nina Maria
    Tsatsani, Georgia
    Koufakis, Theocharis
    Kotsa, Kalliopi
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (02) : 185 - 196
  • [30] Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches
    Lenzen, Sigurd
    Joerns, Anne
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2024, 102 (12): : 1451 - 1455
12345